Telix Pharmaceuticals submits European marketing authorisation application for prostate cancer imaging product
30. April 2020 20:14 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, May 01, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has submitted a marketing...
Telix Pharmaceuticals and GE Healthcare: Maximising 68Ga Supply for Prostate Cancer Imaging
13. Oktober 2019 19:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix”, the “Company”) a clinical-stage biopharmaceutical company focused on the development of...
Telixが日本で腎臓がん用画像診断薬の臨床治験を開始
29. August 2019 20:00 ET
|
Telix Pharmaceuticals Limited
メルボルン, オーストラリア および京都, 日本, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals...
Telix Pharmaceuticals to Launch Japanese Renal Cancer Imaging Study
29. August 2019 20:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the...
Telix Completes Acquisition of Atlab for Prostate Cancer Program
10. September 2018 19:30 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NANTES, France, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (“Telix”, the “Company”) today announced completion of the acquisition of Atlab Pharma SAS...